Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer.

Pegylated liposomal doxorubicin (PLD) is a nano-doxorubicin anticancer agent. It was used as early as 2014 to treat ovarian and breast cancer, multiple myeloma and Kaposi's sarcoma. The 2018 National Comprehensive Cancer Network guidelines listed PLD as first-line chemotherapy for ovarian cancer. PLD has significant anticancer efficacy and good tolerance. Although PLD significantly reduces the cardiotoxicity of conventional doxorubicin, its cumulative-dose cardiotoxicity remains a clinical concern. This study summarizes the high-risk factors for PLD-induced cardiotoxicity, clinical dose thresholds, and cardiac function testing modalities. For patients with advanced, refractory, and recurrent malignant tumors, the use of PLD is still one of the most effective strategies in the absence of evidence of high risk such as cardiac dysfunction, and the lifetime treatment dose should be unlimited. Of course, they should also be comprehensively evaluated in combination with the high-risk factors of the patients themselves and indicators of cardiac function. This review can help guide better clinical use of PLD.

Added value of subjective assessed functional capacity before non-cardiac surgery in predicting postoperative myocardial injury.

BACKGROUND: Functional capacity is used as an indicator for cardiac testing before non-cardiac surgery and is often performed subjectively. However, the value of subjectively estimated functional capacity in predicting cardiac complications is under debate. We determined the predictive value of subjectively assessed functional capacity on postoperative cardiac complications and mortality. DESIGN: An observational cohort study in patients aged 60 years and over undergoing elective inpatient non-cardiac surgery in a tertiary referral hospital. METHODS: Subjective functional capacity was determined by anaesthesiologists. The primary outcome was postoperative myocardial injury. Secondary outcomes were postoperative inhospital myocardial infarction and one year mortality. Logistic regression analysis and area under the receiver operating curves were used to determine the added value of functional capacity. RESULTS: A total of 4879 patients was included; 824 (17%) patients had a poor subjective functional capacity. Postoperative myocardial injury occurred in 718 patients (15%). Poor functional capacity was associated with myocardial injury (relative risk (RR) 1.7, 95% confidence interval (CI) 1.5-2.0; P < 0.001), postoperative myocardial infarction (RR 2.9, 95% CI 1.9-4.2; P < 0.001) and one year mortality (RR 1.7, 95% CI 1.4-2.0; P < 0.001). After adjustment for other predictors, functional capacity was still a significant predictor for myocardial injury (odds ratio (OR) 1.3, 95% CI 1.0-1.7; P = 0.023), postoperative myocardial infarction (OR 2.0, 95% CI 1.3-3.0; P = 0.002) and one year mortality (OR 1.4, 95% CI 1.1-1.8; P = 0.003), but had no added value on top of other predictors. CONCLUSIONS: Subjectively assessed functional capacity is a predictor of postoperative myocardial injury and death, but had no added value on top of other preoperative predictors.

Clinical evaluation of left ventricular function and morphology using an accelerated k-t sensitivity encoding method in cardiovascular magnetic resonance.

OBJECTIVES: To provide clinical validation of a recent 2D SENSE-based accelerated cardiovascular magnetic resonance (CMR) sequence (accelerated k-t SENSE), investigating whether this technique accurately quantifies left ventricle (LV) volumes, function, and mass as compared to 2D cine steady-state free precession (2D-SSFP). METHODS: Healthy volunteers (n = 16) and consecutive heart failure patients (n = 26) were scanned using a 1.5 T MRI system. Two LV short axis (SA) stacks were acquired: (1) accelerated k-t SENSE (5-6 breath-holds; temporal/spatial resolution: 37 ms/1.82 × 1.87 mm; acceleration factor = 4) and (2) standard 2D-SSFP (10-12 breath-holds; temporal/spatial resolution: 49 ms/1.67 × 1.87 mm, parallel imaging). Ascending aorta phase-contrast was performed on all volunteers as a reference to compare LV stroke volumes (LVSV) and validate the sequences. An image quality score for SA images was used, with lower scores indicating better quality (from 0 to 18). RESULTS: There was a high agreement between accelerated k-t SENSE and 2D-SSFP for LV measurements: bias (limits of agreement) of 2.4% (- 5.4% to 10.1%), 6.9 mL/m2 (- 4.7 to 18.6 mL/m2), - 1.5 (- 8.3 to 5.2 mL/m2), and - 0.2 g/m2 (- 11.9 to 12.3 g/m2) for LV ejection fraction, end-diastolic volume index, end-systolic volume index, and mass index, respectively. LVSV by accelerated k-t SENSE presented good agreement with aortic flow. Interobserver and intraobserver variabilities for all LV parameters were also high. CONCLUSION: The accelerated k-t SENSE CMR sequence is clinically feasible and accurately quantifies LV volumes, function, and mass, with short acquisition time and good image quality.

Cardiac function associated with home ventilator care in Duchenne muscular dystrophy.

PURPOSE: Cardiomyopathy is becoming the leading cause of death in patients with Duchenne muscular dystrophy because mechanically assisted lung ventilation and assisted coughing have helped resolve respiratory complications. To clarify cardiopulmonary function, we compared cardiac function between the home ventilator-assisted and non-ventilator-assisted groups. METHODS: We retrospectively reviewed patients with Duchenne muscular dystrophy from January 2010 to March 2016 at Gangnam Severance Hospital. Demographic characteristics, pulmonary function, and echocardiography data were investigated. RESULTS: Fifty-four patients with Duchenne muscular dystrophy were divided into 2 groups: home ventilator-assisted and non-ventilator-assisted. The patients in the home ventilator group were older (16.25±1.85 years) than those in the nonventilator group (14.73±1.36 years) (P=0.001). Height, weight, and body surface area did not differ significantly between groups. The home ventilator group had a lower seated functional vital capacity (1,038±620.41 mL) than the nonventilator group (1,455±603.12 mL). Mean left ventricular ejection fraction and fractional shortening were greater in the home ventilator group, but the data did not show any statistical difference. The early ventricular filling velocity/late ventricular filling velocity ratio (1.7±0.44) was lower in the home ventilator group than in the nonventilator group (2.02±0.62). The mitral valve annular systolic velocity was higher in the home ventilator group (estimated ß, 1.06; standard error, 0.48). Patients with Duchenne muscular dystrophy on a ventilator may have better systolic and diastolic cardiac functions. CONCLUSION: Noninvasive ventilator assistance can help preserve cardiac function. Therefore, early utilization of noninvasive ventilation or oxygen may positively influence cardiac function in patients with Duchenne muscular dystrophy.

Cardiac function associated with home ventilator care in Duchenne muscular dystrophy / 소아과

PURPOSE: Cardiomyopathy is becoming the leading cause of death in patients with Duchenne muscular dystrophy because mechanically assisted lung ventilation and assisted coughing have helped resolve respiratory complications. To clarify cardiopulmonary function, we compared cardiac function between the home ventilator-assisted and non-ventilator-assisted groups. METHODS: We retrospectively reviewed patients with Duchenne muscular dystrophy from January 2010 to March 2016 at Gangnam Severance Hospital. Demographic characteristics, pulmonary function, and echocardiography data were investigated. RESULTS: Fifty-four patients with Duchenne muscular dystrophy were divided into 2 groups: home ventilator-assisted and non-ventilator-assisted. The patients in the home ventilator group were older (16.25±1.85 years) than those in the nonventilator group (14.73±1.36 years) (P=0.001). Height, weight, and body surface area did not differ significantly between groups. The home ventilator group had a lower seated functional vital capacity (1,038±620.41 mL) than the nonventilator group (1,455±603.12 mL). Mean left ventricular ejection fraction and fractional shortening were greater in the home ventilator group, but the data did not show any statistical difference. The early ventricular filling velocity/late ventricular filling velocity ratio (1.7±0.44) was lower in the home ventilator group than in the nonventilator group (2.02±0.62). The mitral valve annular systolic velocity was higher in the home ventilator group (estimated β, 1.06; standard error, 0.48). Patients with Duchenne muscular dystrophy on a ventilator may have better systolic and diastolic cardiac functions. CONCLUSION: Noninvasive ventilator assistance can help preserve cardiac function. Therefore, early utilization of noninvasive ventilation or oxygen may positively influence cardiac function in patients with Duchenne muscular dystrophy.

Comparison of volumetric and functional parameters in simultaneous cardiac PET/MR: feasibility of volumetric assessment with residual activity from prior PET/CT.

OBJECTIVE: To compare cardiac left ventricular (LV) parameters in simultaneously acquired hybrid fluorine-18-fluorodeoxyglucose ([18F] FDG) positron emission tomography/magnetic resonance imaging (PET/MRI) in patients with residual tracer activity of upstream PET/CT. METHODS: Twenty-nine patients (23 men, age 58±17 years) underwent cardiac PET/MRI either directly after a non-cardiac PET/CT with homogenous cardiac [18F] FDG uptake (n=20) or for viability assessment (n=9). Gated cardiac [18F] FDG PET and cine MR sequences were acquired simultaneously and evaluated blinded to the cross-imaging results. Image quality (IQ), end-diastolic (LVEDV), end-systolic volume (LVESV), ejection fraction (LVEF) and myocardial mass (LVMM) were measured. Pearson correlation and intraclass correlation coefficient (ICC), regression and a Bland-Altman analysis were assessed. RESULTS: Except LVMM, volumetric and functional LV parameters demonstrated high correlations (LVESV: r=0.97, LVEDV: r=0.95, LVEF: r=0.91, LVMM: r=0.87, each p<0.05), but wide limits of agreement (LOA) for LVEDV (-25.3-82.5ml); LVESV (-33.1-72.7ml); LVEF (-18.9-14.8%) and LVMM (-78.2-43.2g). Intra- and interobserver reliability were very high (ICC≥0.95) for all parameters, except for MR-LVEF (ICC=0.87). PET-IQ (0-3) was high (mean: 2.2±0.9) with significant influence on LVMM calculations only. CONCLUSION: In simultaneously acquired cardiac PET/MRI data, LVEDV, LVESV and LVEF show good agreement. However, the agreement seems to be limited if cardiac PET/MRI follows PET/CT and only the residual activity is used. KEY POINTS: • [ 18 F] FDG PET-MRI is feasible with residual [ 18 F] FDG activity in patients with homogenous cardiac uptake. • Cardiac volumes and function assessed by PET/MRI show good agreement. • LVEDV and LVESV are underestimated; PET overestimates LVMM and LVEF. • Cardiac PET and MRI data correlate better when acquired simultaneously than sequentially. • PET and MRI should not assess LV parameters interchangeably.

Ventricular Synchronicity Study in Patients of Idiopathic Pulmonary Arterial Hypertension With Different Heart Function by Echocardiography / 中国循环杂志

Objective:To preliminarily study the characteristics of ventricular synchronicity in patients of idiopathic pulmonary arterial hypertension (IPAH) with different heart function. Methods:Our research included in 2 groups:IPAH group, n=40 patients intermittently collected in our hospital from 2010-10 to 2014-12 and Control group, n=23 normal subjects from the same period of time. Tissue Doppler echocardiography was conducted to compare interventricular systolic and diastolic time to peak (Ts and Te), their differences (Te-Ts) and (Te-Ts) of left ventricle (LV), right ventricle (RV), interventricular septum (IVS) between 2 groups. Results:Ts and Te of RV were longer than Ts and Te of LV and IVS in both groups, PIII>IV, all differences had statistic meaning. Conclusion:IPAH patients with different right heart function may have interventricular systolic and diastolic de-synchronicity;by reduced heart function, interventricular Te-Ts could be specifically shortened.

The Value of Two-dimensional Speckle Tracking Echocardiographic Imaging for Assessing Left Ventricular Function at Pre-and Post-percutaneous Coronary Intervention in Patients With Chronic Total Coronary Occlusion / 中国循环杂志

Objective:To explore the value of two-dimensional speckle tracking echocardiographic imaging (2D-STI) for assessing partial and global left ventricular functional changes at pre-and post-percutaneous coronary intervention (PCI) in patients with chronic total coronary occlusion. Methods:Echocardiograph was conducted in 23 chronic total coronary occlusion patients at pre-PCI and 1 day, 3, 6 months post-PCI to examine left ventricular ejection fraction (LVEF), meanwhile 2D-STI was applied to obtain the global longitudinal strain (GLS) value of left ventricle. Results:In all 23 patients, for LVEF, compared with pre-PCI (59.29±12.15)%, it was increased at 3 and 6 months post-PCI (60.00±12.35)%and (61.37±11.8)%respectively, all P Conclusion:PCI could effectively improve left ventricular function in patients with chronic total coronary occlusion, 2D-STI technology may quantitatively assess those changes at the early stage.

Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment.

BACKGROUND: Recently, magnetic resonance (MR)-conditional implantable cardioverter defibrillator (ICD) systems have become available. However, associated cardiac MR image (MRI) quality is unknown. The goal was to evaluate the image quality performance of various cardiac MR sequences in a multicenter trial of patients implanted with an MR-conditional ICD system. METHODS AND RESULTS: The Evera-MRI trial enrolled 275 patients in 42 centers worldwide. There were 263 patients implanted with an Evera-MRI single- or dual-chamber ICD and randomized to controls (n=88) and MRI (n=175), 156 of whom underwent a protocol-required MRI (9-12 weeks post implant). Steady-state-free-precession (SSFP) and fast-gradient-echo (FGE) sequences were acquired in short-axis and horizontal long-axis orientations. Qualitative and quantitative assessment of image quality was performed by using a 7-point scale (grades 1-3: good quality, grades 6-7: nondiagnostic) and measuring ICD- and lead-related artifact size. Good to moderate image quality (grades 1-5) was obtained in 53% and 74% of SSFP and FGE acquisitions, respectively, covering the left ventricle, and in 69% and 84%, respectively, covering the right ventricle. Odds for better image quality were greater for right ventricle versus left ventricle (odds ratio, 1.8; 95% confidence interval, 1.5-2.2; P<0.0001) and greater for FGE versus SSFP (odds ratio, 3.5; 95% confidence interval, 2.5-4.8; P<0.0001). Compared with SSFP, ICD-related artifacts on FGE were smaller (141±65 versus 75±57 mm, respectively; P<0.0001). Lead artifacts were much smaller than ICD artifacts (P<0.0001). CONCLUSIONS: FGE yields good to moderate quality in 74% of left ventricle and 84% of right ventricle acquisitions and performs better than SSFP in patients with an MRI-conditional ICD system. In these patients, cardiac MRI can offer diagnostic information in most cases. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02117414.

Effect of autophagy and mitochondrial coenzyme Q on cardiac function of rats with acute sepsis / 中华实用儿科临床杂志

Objective To investigate the effects of autophagy on cardiac function and to determine whether the mitochondrial coenzyme Q (MitoQ) prevents cardiac dysfunction,mediated by autophagy,in rats with acute sepsis.Methods Forty-five Sprague Dawley (SD) rats were randomly divided into 9 groups (n =5,each group):control group,4 h lipopolysaccharide(LPS) group,6 h LPS group,12 h LPS group,4 h LPS + Wortmannin group,4 h LPS + MitoQ group,6 h LPS + MitoQ group,MitoQ group and Wortmannin group.Rats in LPS + Wortmannin group and LPS + MitoQ group were intraperitoneally given LPS(10 mg/kg) and followed by an injection of Wortmannin(2 mg/kg) and MitoQ (6.5 μmol/kg) via tail vein 1 hour later,respectively.Rats in each group were given the same amount of normal sodium in addition to different intervention drugs.The cardiac function parameters were measured by a BL-420E + biosignal collection system.Blood samples from abdominal aorta were taken at each time point,and creatine kinase MB isoenzyme (CK-MB) content was detected by using the velocity method.The content of reactive oxygen species (ROS) in isolated myocardial tissues in rats was measured by enzyme-linked immunoadsorbent assay(ELISA).The protein expression of microtubule-associated protein 1 light chain 3 (LC3) was detected by Western blot method.The pathological changes of myocardial tissue were observed by light and electronic microscopy.Results Compared with the control group,the left ventricular systolic pressure(LVSP),the rate of the rise in left ventricular pressure (± dp/dt max) were significantly decreased in 6 h LPS group,6 h LPS + MitoQ group and 4 h LPS + Wortmannin group(P ＜0.05),left ventricular end-diastolic pressure(LVEDP) was significantly increased in these 3 groups(P ＜0.05).The contents of CKMB and ROS in 6 h LPS group,6 h LPS =MitoQ group and 4 h LPS + Wortmannin group were higher than those in the control group(P ＜ 0.05).Electron microscopy showed that the number of autophagic vacuoles increased 6 h after LPS was administered,but did not increase significantly thereafter to 12 h.There was no difference at any time point in the number of autophagic vacuoles in the group given MitoQ and LPS.Immunoblotting demonstrated that the levels of LC3Ⅱ protein in the LPS 6 h group and LPS + MitoQ 6 h group were higher than those in the control group(P ＜0.05),but there was no difference between the LPS 12 h and LPS 6 h groups (P ＞ 0.05).Conclusions The mitochondria-targeted antioxidant MitoQ does not prevent cardiac dysfunction.However,autophagy prevents cardiac dysfunction,and the autophagic capacity or autophagosome-formation rate may determine whether cardiac dysfunction develops.

Diagnóstico oportuno del daño al miocardio en pacientes tratados con antraciclinas: un reto para el siglo XXI / Timely diagnosis of myocardial damage in patients treated with anthracyclines: a challenge for the 21st century

Introducción. Los métodos utilizados actualmente para la valoración del daño miocárdico en pacientes tratados con antraciclinas presentan deficiencias para la detección del daño incipiente. La troponina I forma parte de las proteínas reguladoras de la maquinaria de contracción en la miofibrilla y se ha utilizado como biomarcador específico de daño miocárdico. El objetivo de este trabajo fue comparar los niveles de troponina I en pacientes tratados con antraciclinas, antes y después de un nuevo ciclo de quimioterapia. Métodos. Se incluyeron pacientes con diagnóstico de cáncer, de 9 a 18 años, que recibían tratamiento con antraciclinas en el Hospital Infantil de México Federico Gómez. Se midieron los niveles séricos de troponina I (antes y después de un nuevo ciclo de quimioterapia) y se compararon los resultados obtenidos. Resultados. El promedio de la dosis acumulada de antraciclinas en la población estudiada fue de 234 mg/m²SC para daunorrubicina y 269 mg/m²SC para doxorrubicina. No se observó una disfunción sistólica importante mediante el ecocardiograma pero, mediante uso de SPEC-CT, sí se observaron alteraciones en la movilidad de las paredes ventriculares izquierdas. No se evidenció un aumento de niveles de troponina I en el suero después de la aplicación de una nueva dosis de antraciclinas. Conclusiones. Se ha investigado mucho acerca de biomarcadores que ayuden al diagnóstico temprano de la cardiopatía secundaria a antraciclinas, pero se han obtenido resultados contradictorios. Tomar en cuenta la cinética de la troponina I en el daño miocárdico, es un paso fundamental para su evaluación. Bajo esta premisa, no se observaron aumentos de este biomarcador en sangre después del daño miocárdico secundario al uso de antraciclinas.

Background. Currently used methods for assessment of myocardial damage in patients treated with anthracyclines are deficient in detecting mild myocardial damage. Troponin I is part of the protein contractile machinery in the myofibril and is used as a specific biomarker of myocardial damage. The aim of the study was to compare troponin I levels in patients with prior anthracycline use after a new cycle of chemotherapy. Methods. We included patients from 9 to 18 years of age who were diagnosed with cancer and being treated with anthracyclines at the Hospital Infantil de Mexico Federico Gomez. We analyzed serum troponin I prior to and after the new cycle of chemotherapy and compared the results, always in a blinded manner. Results. The mean cumulative dose of anthracyclines in the study population was 234 mg/m² SC for daunorubicin and 269 mg/m² SC for doxorubicin. There was no significant systolic dysfunction according to echocardiography. Impaired mobility of left ventricular walls was observed using SPECT-CT. There was no evidence of increased levels of troponin I in serum after application of a new dose of anthracyclines. Conclusions. Extensive research has been carried out in regard to biomarkers that aid in the early diagnosis of cardiomyopathy secondary to anthracycline, with mixed results. Taking into account the kinetics of troponin I in myocardial damage is a critical step for evaluation. Using this premise, we did not find an increase of this biomarker in blood after myocardial damage secondary to administration of anthracyclines.

El ecocardiograma y su papel en niños con cáncer / Role of echocardiogram in children with cancer

Introducción. Actualmente las antraciclinas se han incorporado en más de 50% de los protocolos de tratamiento para cáncer en la población infantil. La utilidad clínica de estos agentes queda limitada por la aparición de cardiomiopatías, cuya presencia depende de la dosis total del fármaco y suele ser irreversible. El ecocardiograma es el estudio más utilizado para la detección de cardiotoxicidad por antraciclinas. El objetivo de este trabajo fue describir la evolución de los índices de funcionamiento cardiaco reportados por ecografía durante el tratamiento de niños con cáncer con esquemas que contenían antraciclinas. Métodos. Se incluyeron pacientes pediátricos con diagnóstico de osteosarcoma y leucemia mieloide aguda tratados entre enero del 2006 y mayo del 2011 en el Hospital Infantil de México Federico Gómez. En el expediente clínico se documentaron los valores de las fracciones de eyección y acortamiento reportadas antes de cada ciclo. Se utilizó estadística descriptiva para el reporte de los resultados. Resultados. La fracción de eyección prácticamente no sufrió variaciones hasta el sexto ciclo de tratamiento a una dosis acumulada de 332.5 mg/m²SC, para posteriormente decaer de forma acelerada. En la fracción de acortamiento el mayor cambio se produjo después del séptimo ciclo, a una dosis acumulada de 450 mg/m²SC. Conclusiones. Reconocer el daño que se produce en etapas tempranas es un paso fundamental en la prevención de complicaciones. El reto es implementar nuevas herramientas que nos permitan alcanzar el objetivo de prevención o de diagnóstico de enfermedad subclínica.

Background. Currently, anthracyclines have been used in >50% of cancer treatment protocols in children. The clinical usefulness of these agents is limited by the onset of cardiomyopathy whose presence depends on the total dose of drug and usually is irreversible. Echocardiography is used to study anthracycline cardiotoxicity detection. The aim of this study was to describe the evolution of cardiac function reported by echocardiography for treatment of children with cancer whose medications contain anthracyclines. Methods. We included pediatric patients diagnosed with osteosarcoma and acute myeloid leukemia treated between January 2006 and May 2011 in the Hospital Infantil de México Federico Gómez. In the clinical files, values were documented for ejection fraction and shortening reported before each cycle, using descriptive statistics for reporting results. Results. The ejection fraction experiences virtually no changes until the 6th cycle of treatment to a cumulative dose of 332.5 mg/m²/sc, afterwards it demonstrates an accelerated decline. According to the shortening fraction, the most significant change occurs after the seventh cycle to a cumulative dose of 450 mg/m²/sc. Conclusions. Recognizing the damage that occurs during the early stages is a critical step in preventing complications. The challenge is to implement new tools that will allow us to achieve the objective of preventing or diagnosing subclinical disease.